Positron is a molecular imaging medical device company that manufactures and sells state-of-the-art PET imaging systems and clinical services to nuclear medicine healthcare providers throughout North America. Positron specializes in the field of cardiac Positron Emission Tomography (PET) imaging. Recognized as the gold standard in diagnostic nuclear imaging, cardiac PET is the most effective method in nuclear cardiology for detecting coronary artery disease. Positron’s innovative PET technology, clinical services and practice solutions enables healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes through providing superior cost-effective medicine. Positron's dedicated PET only system “the Attrius®” and unique market position are substantial advantages in facilitating the adoption of cardiac PET and the growth of the nuclear cardiology imaging market. Positron’s Attrius® offers the latest in cardiac PET technology and is the only choice when looking for a new dedicated PET system. Optimized for MPI, the Attrius provides excellent sensitivity with minimal radiation exposure, when compared to SPECT, and can perform routine quantitative measurements. Positron will soon offer a state-of-the-art PET-CT 4D molecular imaging device that will enable nuclear cardiologists to utilize the full capabilities available in molecular imaging and nuclear medicine. Positron’s PET-CT also allows the Company to expand and service the needs of the vast oncology diagnostics marketplace. Positron is committed to the future of PET imaging and will continue to advance the technology through its production and R&D venture with Neusoft Medical Systems. Positron was founded in 1983 and is based in Niagara Falls, NY.